Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Italy

 

Pantheon stalks the managed equipment services market

Entire countries are moving from buying medtech and consumables outright to service models using new intermediaries - so-called managed equipment and multi vendor service integrators. These can service, buy, run and finance all medtech products. Pantheon Healthcare Group, backed by a company owned by the Permira Funds, is moving into Saudi Arabia, where it sees huge potential and hopes to be closing many large contracts in the near term. Founder and Director Rob Piconi and Chief Scientific Officer Stephen Hodgson say that the public sector in Hungary, Saudi Arabia, the Netherlands, Canada, Sweden, the UK, Italy and New Zealand are among many developed and emerging market countries that have adopted or are looking to adopt the new healthcare service model.
January 12, 2016

It’s official: MPT and AXA buy Policlinico di Monza real estate

As reported here last month, American REIT Medical Properties Trust (MPT) and AXA Insurance Companies have bought eight hospitals off the Italian chain, Policlinico di Monza, for €180m. This is a 50/50 deal transacted through AXA IM – Real Assets.
November 19, 2015

Report: Reforming healthcare – trends and trajectories

European countries are undergoing rapid and substantial demographic and technological changes. Yet, healthcare systems are still mainly state-funded and acute-focused, as they have been for the past 70 years. This is starting to change.
November 4, 2015

MPT and AXA scoop Policlinico di Monza

We hear that the American healthcare REIT Medical Properties Trust (MPT) is buying the real estate of the Italian hospital group Policlinico di Monza. The deal is for eight hospitals with an estimated value of €175m. The Italian daily Il Sore 24 Ore reports that a major French investor is purchasing the property, which is likely to be AXA REIM who is involved in a partnership with MPT.
October 16, 2015

Report: Healthcare Europa Property Survey 2015

There is intense investor interest in healthcare services property across Europe. Fund manager Marc Phillip Martins-Kuenzel, at German real estate investor Corpus Sireo claims that he had 400 approaches from prospective buyers in a single year. This reflects the global search for high yielding investments. But healthcare property also carries risks. Some sectors such as the French hospital market, where major deals have been done, look risky as the government cuts tariffs. And the sector remains opaque and poorly segmented. There are plenty of traps for the unwary. It is also far from clear how much new capacity will come on stream for investors over the next decade. Here we look at whether and when the boom will go bust. First, we run through the headlines and what has happened to prices. We then go on to look at supply and demand. Other articles profile the main US and European property investors and the main national markets.
October 2, 2015

Italian care home chain Eukedos starts external growth phase

Eukedos's president, Carlo Iuculano, says he might merge quoted care home group Eukedos where he holds a majority stake with the larger La Villa chain, which he also controls. This would create a group with 38 nursing homes and 3,200 beds, the third largest after Korian and Kos.
September 11, 2015

Ardian to sell 47% stake in Kos for at least €235m

Private equity house Ardian is to sell its 47% stake in Italian care group KOS. The likely buyer is CIR, the conglomerate which holds a majority stake in KOS, although many private equity houses are also interested in the stake which has almost certainly got “drag along rights”. Those would enable any buyer to force CIR to sell if a bidder came along for the entirety of KOS.
September 11, 2015

Cinven’s €3 billion bet on labs

Cinven has placed a €3bn bet on the European diagnostic laboratory space, by agreeing to pay a higher than expected €1.85bn for synlab Group, a multiple of just over 12 times current EBITDA. It will combine synlab with Labco to create a truly Pan-European lab group with pro-forma 2014 sales of just over €1.4bn, nearly twice that of its nearest rival. But why bet €3bn on a sector where tariffs are falling and operators have no control over pricing? And could the French authorities block the deal?
June 26, 2015
Older posts
Newer posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us